- 询价
- 2025年11月22日
14 年金牌会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 技术资料
- 细胞形态：
其他
- 物种来源：
人
- 是否是肿瘤细胞：
0
- 细胞类型：
其他细胞类型
- 器官来源：
外周血
- 运输方式：
冻存运输
- 相关疾病：
其他疾病
- ATCC Number：
CRL-2775™
- 生长状态：
悬浮生长
- 年限：
64 years adult
- 库存：
大量
| Designations: | Kasumi-6 | ||
| Depositors: | H Asou | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | suspension | ||
| Organism: | Homo sapiens | ||
| Morphology: | myeloid leukemia |
||
| Source: | Organ: peripheral blood Disease: acute myeloid leukemia, subtype M2 Cell Type: myeloblast |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Isolation: | Japan Isolation date: January 1999 |
||
| DNA Profile (STR): | Amelogenin: X,Y CSF1PO: 10,12 D13S317: 8,12 D16S539: 9,10 D5S818: 11 D7S820: 9,11 THO1: 6,9 TPOX: 8,9 vWA: 17 |
||
| Cytogenetic Analysis: | 45, XY,-9,add(12)(p11),add(13)(p11) [88888 ] | ||
| Age: | 64 years adult | ||
| Gender: | male | ||
| Ethnicity: | Japanese | ||
| Comments: | AntigenExp: CD33+, CD13+, CD11b+, HLA-DR+, CD3-, CD14-, CD19-, CD41-, CD34 -Oncogene: c-kit +Products: Myeloperoxidase, negativeC/EBP-alpha, hemizygous mutation protein positiveComments: The cell line was established from the blast cells of a myeloperoxidase-negative patient with relapsed acute myeloid leukemia (AML), FAB M2. The patient had received prior chemotherapy. Both the original leukemic cells and the Kasumi-6 cell line harbor a hemizygous point mutation in the gene encoding the CCAAT/enhancer binding protein alpha (C/EBPalpha), a critical myeloid transcriptional factor. The cells express C/EBPalpha protein but lack C/EBPalpha binding activity. 12-O-tetradecanoylphorbol-13-acetate (TPA) induces Kasumi- 6 cells to differentiate into adherent, monocytoid appearing cells. The Kasumi-6 cell line can serve as a model to study the cellular and molecular biology of the non-t(8;21) M2 type of myeloid leukemia and can elucidate the role of mutated C/EBPalpha in leukemogenesis. |
||
| Propagation: | ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate supplemented with 2 ng/ml human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) and 20% fetal bovine serum Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
||
| Subculturing: | Protocol: Cultures can be established by centrifugation with subsequent resuspension at 2 X 10(5) viable cells/ml. Maintain cell density between 2 X 10(5) and 1.5 X 10(6) viable cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
||
| Preservation: | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
||
| Doubling Time: | 55 hrs | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 |
||
| Bioreactive Factors: | Differentiation Inducers: TPA | ||
| References: | 88888: Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245 | ||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
技术资料暂无技术资料 索取技术资料
Kasumi-6
询价
